Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$10.53 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $10.58 +0.05 (0.47%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Balance Sheet
Fiscal Year End for Rigel Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 57 | 58 | 125 | 57 | 98 |
Receivables | 31 | 40 | 15 | 16 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 9 | 7 | 2 | 1 |
Other Current Assets | 6 | 8 | 7 | 14 | 9 |
Total Current Assets | 99 | 116 | 154 | 89 | 119 |
Net Property & Equipment | 0 | 1 | 2 | 3 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 14 | 15 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 1 | 1 | 1 | 1 |
Total Assets | 117 | 134 | 167 | 110 | 148 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 7 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 23 | 4 | 4 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 18 | 23 | 34 | 26 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 21 | 19 | 16 | 3 | 25 |
Total Current Liabilities | 53 | 65 | 64 | 41 | 58 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 52 | 39 | 20 | 20 | 10 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 40 | 42 | 53 | 5 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 146 | 148 | 137 | 76 | 94 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,379 | 1,369 | 1,354 | 1,340 | 1,330 |
Retained Earnings | -1,408 | -1,382 | -1,324 | -1,306 | -1,276 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -29 | -14 | 30 | 34 | 54 |
Total Liabilities & Shareholder's Equity | 117 | 134 | 167 | 110 | 148 |
Total Common Equity | -29 | -14 | 30 | 34 | 54 |
Shares Outstanding | 17.40 | 17.20 | 17.10 | 16.90 | 16.70 |
Book Value Per Share | -1.65 | -0.79 | 1.78 | 2.01 | 3.22 |
Fiscal Year End for Rigel Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 50 | 57 | 62 | 64 |
Receivables | NA | 28 | 31 | 24 | 21 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 7 | 6 | 6 | 11 |
Other Current Assets | NA | 9 | 6 | 3 | 5 |
Total Current Assets | NA | 92 | 99 | 95 | 101 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 29 | 14 | 14 | 14 |
Deposits & Other Assets | NA | 4 | 3 | 5 | 1 |
Total Assets | NA | 127 | 117 | 115 | 117 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 15 | 7 | 0 | 0 |
Accounts Payable | NA | 9 | 7 | 8 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 15 | 18 | 19 | 18 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 34 | 21 | 21 | 21 |
Total Current Liabilities | NA | 73 | 53 | 48 | 44 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 45 | 52 | 60 | 60 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 40 | 39 | 41 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 158 | 146 | 147 | 145 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,384 | 1,379 | 1,376 | 1,374 |
Retained Earnings | NA | -1,416 | -1,408 | -1,408 | -1,403 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -32 | -29 | -32 | -28 |
Total Liabilities & Shareholder's Equity | NA | 127 | 117 | 115 | 117 |
Total Common Equity | 0 | -32 | -29 | -32 | -28 |
Shares Outstanding | 17.50 | 17.50 | 17.40 | 17.40 | 17.40 |
Book Value Per Share | 0.00 | -1.81 | -1.65 | -1.83 | -1.62 |